查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1560331

先進治療市場報告：2030 年趨勢、預測與競爭分析

Advanced Therapy Medicinal Products Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

先進治療藥物的趨勢與預測

到2030年，全球先進治療藥物（ATMP）市場預計將達到199億美元，2024年至2030年的複合年成長率為13.5%。該市場的關鍵促進因素是醫療保健支出的增加、慢性病盛行率的增加、有利的法規環境和政府支持的擴大。全球先進治療藥物市場前景廣闊，細胞治療、CAR-T治療、基因治療和組織工程產品市場充滿機會。

在這個市場中，組織工程產品將繼續成為最大的細分市場，因為它們在創傷治療和再生醫學應用中的應用越來越廣泛。

由於癌症、心血管疾病和神經退化性疾病等慢性疾病的高盛行率，北美將繼續成為最大的市場。

先進治療藥物市場新趨勢

有幾個關鍵趨勢正在重塑先進醫學格局並導致先進治療市場的發展。其中包括技術、監管和研究重點的變化，這些變化將影響 ATMP 的開發和採用。

  • 人工智慧和機器學習的整合：利用人工智慧 (AI) 和機器學習進行 ATMP 開發和最佳化的趨勢日益明顯。人工智慧被用來分析複雜的生物資料，識別潛在的治療靶點，並簡化開發過程。這種整合將確保治療的準確性並縮短新藥的上市時間。
  • 個人化醫療的擴展：個人化醫療正在主導 ATMP 市場。基因組學和生物技術的進步使得為具有不同基因的人開發治療方法成為可能。最大限度地減少副作用和改善治療是開發有效治療方法整個計劃的重點。
  • 推動再生醫學的創新：組織工程、幹細胞療法和其他再生醫學如今正在迅速發展。從退化性疾病到創傷，這些進步為解決醫療問題提供了新方法。再生醫學領域正在創造機會並擴大 ATMP 的範圍。
  • 增加監管支援：目前世界各地對 ATMP 開發和核准的監管支援正在增加。簡單的認證方法和最新的指南有助於將新治療方法更快地推向市場。這表明世界不僅有興趣改善患者獲得更好治療方法的機會，而且也有興趣鼓勵發明。

ATMP 市場的新趨勢正在再形成先進治療領域，包括人工智慧整合、再生醫學創新、個人化醫療和監管支援。最終，這些趨勢將推動該細分市場的成長，因為它們會改善 ATMP 的開發、療效並改善患者的治療結果。

新興市場開拓的最新趨勢

最近的趨勢正在影響先進治療市場的發展。這種變化是由基因和細胞療法的創新、技術突破以及監管進步所推動的。因此，這些進步不僅增加了治療方法選擇，也提高了價格和效率，塑造了全球市場趨勢。

  • 新型基因療法的核准：最近新型基因療法的核准對 ATMP 市場產生了重大影響。這些療法為治療曾經被認為無法治癒的遺傳性疾病提供了新的可能性。例如，Zolgensma用於脊髓性肌肉萎縮症的基因療法的核准表明基因療法可以針對罕見和複雜的疾病，並且其他類似的突破性努力將隨之而來，人們認為這將繼續下去。
  • CAR-T細胞療法的進展：隨著新治療方法的引入和現有治療方法適應症的擴大，嵌合體抗原受體T細胞（CAR-T）療法取得了重大進展。例如，Kymriah 和 Yescarta 是其中的一些治療方法，它們對某些癌症表現出良好的療效，從而擴大了治療選擇，並導致了我所做的 ATMP 市場的腫瘤學領域的成長。
  • 擴大法規結構：法律規範的製定和完善促進了 ATMP 的推進和核准。監管機構正在透過創建快速核准流程並提供更清晰的指示來簡化從研究到市場的路徑。這些進步對於支持先進療法的創新和商業化是必要的。
  • 個人化醫療的整合： ATMP 中個人化醫療方法的整合正在迅速進展。次世代定序等技術擴大實現基於個人基因圖譜的客製化治療。這種客製化提高了治療效果，反映了個人化醫療的成長趨勢。

ATMP 市場正在受到近期趨勢的顯著影響，例如基因和細胞療法的進步、管理該領域的法規的改進以及投資的增加。這些事件透過擴大患者可用的治療選擇、改善患者的治療結果並為 ATMP 的進一步創新和進步奠定基礎，推動市場成長。

先進治療市場的策略性成長機會

先進治療市場在各種應用中都有幾個策略性成長機會。技術的進步、患者需求的增加以及支持性的法規環境提供了這些機會。透過開拓這些細分市場可以促進市場擴張，從而帶來未來突破性的治療方法。

  • 擴大癌症治療：ATMP 市場的腫瘤領域具有顯著的成長前景。 CAR-T 創新和其他以細胞為基礎的治療方法為無反應性癌症疾病提供了新的治療選擇。將這些治療方法擴展到更廣泛的患者和不同的癌症代表著一個重大的成長機會。
  • 罕見疾病治療發展：罕見疾病和罕見疾病治療方法的開發是主要的成長領域。針對特定遺傳疾病的基因療法和其他先進療法正變得越來越普遍。除了解決以前未滿足的醫療需求之外，這種方法還吸引了大量投資和監管支援。
  • 再生醫學的進展：再生醫學領域透過幹細胞療法和組織工程正在迅速發展。在修復和替換受損組織和器官方面還有很大的成長空間。但發明可以為心臟病、脊椎損傷和神經退化疾病提供新的治療方法。
  • 數位醫療技術的融合：ATMP 和數位醫療技術的結合可以成為成長的機會。這些數位工具可以透過監測患者、收集資料和最佳化治療來提高這些治療方法的有效性。這增加了增強的解決方案，例如個人化治療方法以及改進的患者管理。

ATMP 市場的策略性成長機會包括癌症治療、罕見疾病治療、再生醫學、數位健康整合以及向新興市場擴張的進步。這些有可能顯著成長市場。這些機會促進了創新治療方法的發展並改善了全球患者照護。

先進治療藥物市場推廣因素及挑戰

先進治療市場的開拓和成長受到多種市場促進因素和挑戰的影響。這些分別包括技術進步、監管支援和患者需求的增加。然而，該領域最大的挑戰仍然存在，包括成本上升、嚴格的法規和複雜的製造流程。因此，了解這些問題對於成功駕馭市場非常重要。

推動先進治療市場的因素包括：

1.技術進步：基因編輯、細胞治療和再生醫學是ATMP市場的主要驅動力。在疑難雜症的治療方面，包括CRISPR基因編輯工具、CAR-T細胞在內的新技術代表醫學的新成就。結果，他們的影響範圍擴大了，先進的治療方法本身也變得更有效。

2. 監管支持：ATMP 的成長和核准得益於支持性的法規環境。加快的監管核准流程已經到位，更明確的指導方針提供了從研究到商業化的清晰路徑。值得注意的是，創新和市場擴張依賴此類監管支援。

3.患者需求增加：市場擴張的驅動力是對先進療法的認知和需求不斷成長。治療方案需要個人化、有效，並且主要針對尋求醫療服務的複雜罕見疾病患者。這種需求繼續推動 ATMP 領域進行進一步的研究和開發。

先進治療藥物市場問題如下。

1.高成本：開發和製造ATMP的挑戰之一是其高成本。這些治療方法複雜且研究和製造成本高昂，限制了治療的獲得並抑制了市場成長。為了更廣泛的採用和永續性，解決成本問題非常重要。

2. 監理障礙：透過 ATMP法律規範既複雜又耗時。儘管有法律體制，但嚴格的要求使公司很難獲得核准。成功的市場進入要求這些公司密切管理所有監管流程。

3.製造複雜性：ATMP的製造過程涉及複雜的程序和品管步驟。保持一致的產品品質和可擴展性可能很困難，並且會導致製造效率低下和成本高昂。克服這些挑戰對於滿足市場需求同時確保產品可靠性至關重要。

雖然技術進步、不斷成長的患者需求和監管支援是影響先進治療藥物 (ATMPS) 市場的促進因素和挑戰，但其他挑戰包括高成本、監管障礙和製造複雜性等。這些促進因素需要與這些障礙同時解決，從而促進該領域的更多創新，擴大市場成長率，並更有效地利用先進醫療設施的專利保護。

按細分市場分類的先進療法

該調查按產品和地區對全球先進治療藥物進行了預測。

先進治療藥物市場的國家前景

由於基因治療、細胞治療和再生醫學的市場開拓，全球先進治療藥物市場正在發生重大變化。這些變化正在定義一種注重個人化治療、更好的表現和更廣泛的覆蓋範圍的護理形式。美國、中國、德國、印度和日本是透過各種方式為先進治療市場的成長和轉型做出貢獻的關鍵國家。

  • 美國：美國在 ATMP 方面取得了重大進展，重點是基因和細胞療法的接受和商業化。 FDA 最近批准了多種針對備受矚目的遺傳疾病和癌症的治療方法，導致該領域出現更多發明和成長。新的指南設置和資助計劃也正在推動這一領域的研究。
  • 中國：隨著大力投資開發 CRISPR 基因編輯技術和細胞治療方法臨床試驗的進展，中國正迅速轉向 ATMP。因此，透過政策變革和中國政府的資助，先進治療方法的開發速度更快，使該公司成為全球市場的主要參與企業之一。
  • 德國：德國透過發展再生醫學和幹細胞研究，鞏固了其在先進治療市場的地位。例如，細胞和基因治療研究專門中心的建立正在促進科學家之間的創造力和合作。此外，德國的監管基礎設施正在發生變化，以便能夠將 ATMP 安全地融入臨床實踐。
  • 印度：在印度，ATMP 市場正在擴大，越來越注重開發廉價且易於取得的基因和細胞療法。此外，新的生物技術進步和政府支持政策正在推動市場擴張。此外，印度公司透過國際合作推動研究並將新治療方法推向市場，為全球 ATMP 開發做出貢獻。
  • 日本：日本在再生醫學領域處於領先地位，在幹細胞治療和基因編輯方面取得了重大進展。日本政府透過投資界促進 ATMP核准並促進創新。此外，日本目前致力於將先進的治療方法直接引入主流醫療服務，從而改善患者的選擇。

常問問題

Q.1 先進治療藥物的市場規模有多大？

答：到 2030 年，全球先進治療市場預計將達到 199 億美元。

Q.2 先進治療藥物市場的成長預測如何？

答：2024年至2030年，全球先進治療市場預計將以13.5%的複合年成長率成長。

Q.3 影響先進治療市場成長的關鍵促進因素有哪些？

答：這個市場的主要驅動力是醫療保健支出的增加、慢性病盛行率的上升、有利的法規環境和政府支持的增加。

Q4.市場的主要細分市場是什麼？

答：先進治療市場的未來前景廣闊，細胞治療、CAR-T治療、基因治療和組織工程產品市場都有機會。

Q5.市場上主要企業有哪些？

答：主要的先進療法公司有：

  • Spark Therapeutics
  • Bluebird Bio
  • Novartis
  • Uniqure
  • Celgene Corporation
  • Gilead Lifesciences
  • Kolon Tissue gene
  • JCR Pharmaceuticals
  • Medipost
  • Vericel Corporation

Q6.未來五年預計哪個地區的市場規模最大？

答：由於癌症、心血管疾病和神經退化性疾病等慢性病的高盛行率，北美仍將是最大的細分市場。

Q7. 可以客製化報告嗎？

答：是的，Lucintel 列出了 10% 的客製化服務，無需額外費用。

目錄

第1章執行摘要

第2章全球先進治療藥物市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球先進治療藥物市場趨勢（2018-2023）與預測（2024-2030）
  • 按產品分類的全球先進治療市場
    • 細胞療法
    • CAR-T療法
    • 基因治療
    • 組織工程產品

第4章 2018-2030年區域市場趨勢及預測分析

  • 按地區分類的全球先進療法市場
  • 北美先進治療藥物市場
  • 歐洲先進治療藥物市場
  • 亞太先進治療市場
  • 其他地區先進治療藥物市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按產品分類的全球先進治療市場成長機會
    • 按地區分類的全球先進治療市場成長機會
  • 全球先進治療市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球先進治療藥物市場產能
    • 全球先進治療市場的合併、收購和合資企業
    • 認證和許可

第7章主要企業概況

  • Spark Therapeutics
  • Bluebird Bio
  • Novartis
  • UniQure
  • Celgene Corporation
  • Gilead Lifesciences
  • Kolon TissueGene
  • JCR Pharmaceuticals
  • MEDIPOST
  • Vericel Corporation
簡介目錄

Advanced Therapy Medicinal Products Trends and Forecast

The future of the global advanced therapy medicinal products market looks promising with opportunities in the cell therapy, CAR-T therapy, gene therapy, and tissue engineered product markets. The global advanced therapy medicinal products market is expected to reach an estimated $19.9 billion by 2030 with a CAGR of 13.5% from 2024 to 2030. The major drivers for this market are rising healthcare spending, increasing prevalence of chronic diseases, and favorable regulatory environment and growing government support.

Within this market, tissue engineered product will remain the largest segment due to its increasing adoption in wound healing and regenerative medicine applications.

North America will remain the largest segment due to high prevalence of chronic diseases, such as cancer, cardiovascular diseases, and neurodegenerative diseases.

Emerging Trends in the Advanced Therapy Medicinal Products Market

There are several key trends that are reshaping the landscape of advanced medical treatments, leading to an evolution of the advanced therapy medicinal products (ATMPs) market. These include changes in technology, regulations and research priorities, which shape the development and adoption of ATMPs.

  • Integration of AI and Machine Learning: It is a growing trend to use artificial intelligence (AI) and machine learning for developing and optimizing ATMPs. This is where AI is used to analyze complex biological data, identify potential targets for therapy, streamline development processes among others. The integration ensures accuracy in treatment while speeding up time-to-market for new drugs.
  • Personalised Medicine Expansion: Personalised medicine is dominating the ATMP market. Genomics and biotechnology are becoming more advanced making it possible to create therapies for people with different genes. The entire plan is focused on ensuring that treatment is improved with minimal side effects in order to develop effective therapeutic agents.
  • Innovations Driving Regenerative Medicine: Tissue engineering, stem cell therapy and other facets of regenerative medicine are rapidly advancing today. From degenerative diseases to traumatic injuries, these advancements offer new approaches for dealing with medical conditions. The area of regenerative medicine has created opportunities, which have in turn increased the scope of ATMPs.
  • Rise in Regulatory Backing: There is now greater support for developing and approving ATMPs by regulatory bodies around the world. Easy approval methods and updated guidelines assist in speeding up the introduction of new therapies into the market. This signifies a worldwide interest in encouraging inventions as well as improving patient access to superior treatments.

The field of advanced therapies is being reshaped by emerging trends in the ATMP market such as AI integration; regenerative medicine innovations; personalized medicine and regulatory support among others. Ultimately these trends are improving development, effectiveness of ATMPs that leads to better patient outcomes thus driving growth in this sector.

Recent Developments in the Advanced Therapy Medicinal Products Market

Recently, there have been significant developments that are influencing the evolution of the advanced therapy medicinal products (ATMPs) market. This transformation is driven by innovations in gene and cell therapies as well as technological breakthroughs and regulatory advancements. Thus, these strides not only increase therapeutic options but also improve their affordability and efficiency, thus shaping the global markets trends.

  • Approval of Novel Gene Therapies: Recent approvals of novel gene therapies have had a marked effect on the ATMP market. These treatments offer new possibilities for treating genetic conditions once deemed incurable. For instance, where gene therapy has been approved for Zolgensma for spinal muscular atrophy, this suggests that gene therapy can target rare or complex disorders and other similar groundbreaking initiatives will follow suit.
  • Advances in CAR-T Cell Therapy: Chimeric Antigen Receptor T-cell (CAR-T) therapy has experienced notable advances with newer therapies being introduced and existing ones expanded indications. For example, Kymriah and Yescarta are some of such treatments which have shown great efficacy against certain forms of cancer thus improving treatment options hence growth in the oncology segment of ATMP market.
  • Expansion of Regulatory Frameworks: A development and refinement of regulatory frameworks has allowed the progress and approval of ATMPs. Regulatory agencies are creating fast-track approval procedures and providing clearer instructions, thus simplifying the path from research to market. These developments are necessary for supporting innovation and commercialization of advanced therapies.
  • Integration of Personalized Medicine: The integration of personalized medicine approaches in ATMPs is on a fast track. Technology such as next-generation sequencing is now enabling tailored therapies that are based on one's own genetic profile. This customization improves treatment efficacy, reflecting the increasing trend towards personalized healthcare.

The ATMP market is being shaped significantly by recent developments that include advancements in gene and cell therapies, improvements in regulations governing the sector, and increased investment. These occurrences are expanding the treatment options available to patients, improving patient outcomes and fueling market growth thereby setting a platform for more innovation and advancement of ATMPs.

Strategic Growth Opportunities for Advanced Therapy Medicinal Products Market

There are several strategic growth opportunities across different applications within advanced therapy medicinal products (ATMPs) market. Technological advancements, increasing patient needs and supporting regulatory environments provide these opportunities. Market expansion can be driven through exploring these areas that can lead to future ground breaking treatments.

  • Expansion of Oncology Treatments: The oncology segment of the ATMP market offers significant growth prospects. CAR-T innovations and other cell-based therapies have presented new treatment alternatives for non-responsive cancer ailments. Expanding these therapies among wide range of patients as well as diverse cancers represents one large opportunity for growth.
  • Rare Disease Therapies Development: Developing therapies for rare and orphan diseases is a major area of growth. Gene therapies for specific genetic conditions are becoming popular and other advanced treatments. Apart from addressing medical needs that have not been met, this approach also attracts huge investments as well as regulatory support.
  • Advances in Regenerative Medicine: The field of regenerative medicine is rapidly evolving through stem cell treatments and tissue engineering. A lot of room for growth exists in repairing or replacing damaged tissues or organs. Inventions can however deliver new remedies to heart ailments-spine injuries-neurodegenerative states.
  • Merging Digital Health Technologies: The use of ATMPs together with digital health technologies could be an opportunity for growth. By employing these digital tools in the monitoring patients, collecting data and optimizing treatment methods, it is possible to enhance the effectiveness of these therapeutic options. This will add enhanced solutions like personalized treatments methods along with improved patient management into this combination.

Strategic growth opportunities in the ATMP market include advancements in oncology treatments, rare disease therapies, regenerative medicine, digital health integration and expansion into emerging markets. These can propel the market to significant growth. Through these opportunities, development of innovative therapies and improving patient care globally is possible.

Advanced Therapy Medicinal Products Market Driver and Challenges

The development and growth of the advanced therapy medicinal products (ATMPs) market are influenced by several drivers and challenges. These include technological advances, regulatory support as well as increased patients' demand respectively. On one hand; increased costs high regulations and complex manufacturing processes remain top challenges regarding this area. To successfully navigate the market therefore, it is critical to understand these issues.

The factors responsible for driving the advanced therapy medicinal products market include:

1. Technological Advancements: Gene editing, cell therapy and regenerative medicine have acted as a major driver for ATMP market. In terms of treatment of incurable diseases novel technologies including CRISPR gene editing tool or CAR-T cells usage represent new achievements in medical sciences. Consequently, their reach has been broadened enhancing their efficiency for advanced therapies themselves.

2. Regulatory Support: The growth and approval of ATMPs are being facilitated by supportive regulatory environments. Accelerated approval processes are being implemented by regulatory agencies as well as clearer guidelines that provide a clear path from research to commercialization. It is important to note that the innovation and market expansion depend on this regulation support.

3. Increasing Patient Demand: Market expansion is driven by increasing awareness and demand for advanced therapies. Treatment options need to be personalized, effective and tailored mainly for patients with complex rare diseases who seek healthcare services. This demand continues to push the ATMP sector towards further research & development.

Challenges in the advanced therapy medicinal products market are:

1. High Costs: One of the challenges in the development and production of ATMPs is their high cost. These therapies are intricate and costly to research and produce, thus limiting access to them and impeding market growth. For broader adoption as well as sustainability it is important to address cost concerns.

2. Regulatory Hurdles: Navigating through ATMP regulatory frameworks can be complex as well as time-consuming. This has been despite establishment of supportive legal frameworks; however, stringent requirements have made it hard for these companies in obtaining approvals. Successful entry into the market necessitates a close management of all regulatory processes by these firms.

3. Manufacturing Complexities: The manufacturing process for ATMPs involves intricate procedures and quality control steps. Maintaining consistent product quality and scalability can prove challenging leading to inefficiency in production and high costs. Overcoming these challenges is important if we want to meet the demands of the market while ensuring that our products remain reliable.

Technological advancements, increasing patient demand, regulatory support among others are some of the drivers influencing advanced therapy medicinal products (ATMPS) market while other challenges include high costs, regulatory hurdles, manufacturing complexities among others. Drivers like this require being tackled alongside such obstacles so that more innovation can take place within this field thereby expanding its market growth rate whereas making sure patents receive better actuation towards advanced medical care facilities.

List of Advanced Therapy Medicinal Products Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies advanced therapy medicinal products companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the advanced therapy medicinal products companies profiled in this report include-

  • Spark Therapeutics
  • Bluebird Bio
  • Novartis
  • Uniqure
  • Celgene Corporation
  • Gilead Lifesciences
  • Kolon Tissue gene
  • JCR Pharmaceuticals
  • Medipost
  • Vericel Corporation

Advanced Therapy Medicinal Products by Segment

The study includes a forecast for the global advanced therapy medicinal products by product and region.

Advanced Therapy Medicinal Products Market by Product [Analysis by Value from 2018 to 2030]:

  • Cell Therapy
  • CAR-T Therapy
  • Gene Therapy
  • Tissue Engineered Product

Advanced Therapy Medicinal Products Market by Region [Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Advanced Therapy Medicinal Products Market

Advanced therapy medicinal products market is changing significantly across the globe as a result of developments in gene and cell therapies, as well as regenerative medicine. These transformations are determining the shape of medical treatments that concentrate on individualized treatments, better performance, and wider reachability. United States, China, Germany, India and Japan are the leading countries in this regard who have contributed differently to grow and change the advanced therapy medicinal products market.

  • United States: In America, there have been significant advancements in ATMPs with emphasis on acceptance and commercialization of genes as well as cell therapies. FDA has recently certified a number of high-profile genetic disorder and cancer treatments resulting to more inventions and growth in the sector. New guidelines setting up and funding initiatives are facilitating researches in this area too.
  • China: With considerable investments made towards CRISPR gene editing technology development alongside progressing clinical trials for cellular based therapies, China is quickly making headways into ATMPs. Thus advanced therapies have been developed more quickly both through policy changes by Chinese government as well as funding from it thereby transforming it into one of key players within global market.
  • Germany: Germany has strengthened its position in the market for Advanced Therapy Medicinal Products (ATMPs) by developing regenerative medicine and stem cell research. For example, the establishment of specialized centers for cell and gene therapy research is promoting creativity and collaboration among the scientists. Moreover, Germany's regulatory infrastructure is changing to allow safe integration of ATMPs into clinical practice.
  • India: In India, the ATMP market is expanding with increasing focus on developing affordable and accessible gene and cell therapies. In addition, emerging biotechnological advancements as well as supportive government policies are pushing for expansion. Furthermore, Indian companies collaborate internationally so as to advance research and bring new therapies to market thereby contributing to global ATMP developments.
  • Japan: Japan is leading in regenerative medicine with notable progress in stem cell therapies and gene editing. The Japanese government has made it easy to approve ATMPs thus encouraging innovation through investment communities. Besides that Japan is now focusing on bringing advanced therapies directly into mainstream healthcare services hence improving choices for patients.

Features of the Global Advanced Therapy Medicinal Products Market

Market Size Estimates: Advanced therapy medicinal products market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Advanced therapy medicinal products size by product and region in terms of value ($B).

Regional Analysis: Advanced therapy medicinal products market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products and regions for the mucopolysaccharidosis treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the advanced therapy medicinal products market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the advanced therapy medicinal products market size?

Answer: The global advanced therapy medicinal products market is expected to reach an estimated $19.9 billion by 2030.

Q.2 What is the growth forecast for advanced therapy medicinal products market?

Answer: The global advanced therapy medicinal products market is expected to grow with a CAGR of 13.5% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the advanced therapy medicinal products market?

Answer: The major drivers for this market are rising healthcare spending, increasing prevalence of chronic diseases and favorable regulatory environment and growing government support.

Q4. What are the major segments for advanced therapy medicinal products market?

Answer: The future of the advanced therapy medicinal products market looks promising with opportunities in the cell therapy, CAR-T therapy, gene therapy, and tissue engineered product markets.

Q5. Who are the key advanced therapy medicinal products market companies?

Answer: Some of the key advanced therapy medicinal products companies are as follows:

  • Spark Therapeutics
  • Bluebird Bio
  • Novartis
  • Uniqure
  • Celgene Corporation
  • Gilead Lifesciences
  • Kolon Tissue gene
  • JCR Pharmaceuticals
  • Medipost
  • Vericel Corporation

Q6. In advanced therapy medicinal products market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment due to high prevalence of chronic diseases, such as cancer, cardiovascular diseases, and neurodegenerative diseases.

Q.7 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the advanced therapy medicinal products market by product (cell therapy, CAR-T therapy, gene therapy, and tissue engineered product), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
  • Market Report

Table of Contents

1. Executive Summary

2. Global Advanced Therapy Medicinal Products Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Advanced Therapy Medicinal Products Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Advanced Therapy Medicinal Products Market by Product
    • 3.3.1: Cell Therapy
    • 3.3.2: CAR-T Therapy
    • 3.3.3: Gene Therapy
    • 3.3.4: Tissue Engineered Product

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Advanced Therapy Medicinal Products Market by Region
  • 4.2: North American Advanced Therapy Medicinal Products Market
    • 4.2.1: North American Advanced Therapy Medicinal Products Market by Product: Cell Therapy, CAR-T Therapy, Gene Therapy, and Tissue Engineered Product
  • 4.3: European Advanced Therapy Medicinal Products Market
    • 4.3.1: European Advanced Therapy Medicinal Products Market by Product: Cell Therapy, CAR-T Therapy, Gene Therapy, and Tissue Engineered Product
  • 4.4: APAC Advanced Therapy Medicinal Products Market
    • 4.4.1: APAC Advanced Therapy Medicinal Products Market by Product: Cell Therapy, CAR-T Therapy, Gene Therapy, and Tissue Engineered Product
  • 4.5: ROW Advanced Therapy Medicinal Products Market
    • 4.5.1: ROW Advanced Therapy Medicinal Products Market by Product: Cell Therapy, CAR-T Therapy, Gene Therapy, and Tissue Engineered Product

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Advanced Therapy Medicinal Products Market by Product
    • 6.1.2: Growth Opportunities for the Global Advanced Therapy Medicinal Products Market by Region
  • 6.2: Emerging Trends in the Global Advanced Therapy Medicinal Products Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Advanced Therapy Medicinal Products Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Advanced Therapy Medicinal Products Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Spark Therapeutics
  • 7.2: Bluebird Bio
  • 7.3: Novartis
  • 7.4: UniQure
  • 7.5: Celgene Corporation
  • 7.6: Gilead Lifesciences
  • 7.7: Kolon TissueGene
  • 7.8: JCR Pharmaceuticals
  • 7.9: MEDIPOST
  • 7.10: Vericel Corporation